Greetings,

Monogram is pioneering an entirely new approach to the orthopedic industry.

How?

With the use of 3D-printed, press-fit implants designed to fit each patient’s unique anatomy for long-lasting health and mobility.

At the moment, cemented implants are the gold standard. But why is this the case when they’re causing serious problems like implant breakage, infections, allergic reactions, and stiff joints?

Unlike mainstream systems, we seek to work with the body, not against it.

Monogram is on track to popularize the use of press-fit implants - prosthetics crafted from porous metal that naturally allows the bone to fuse onto the implant and securely hold it in place.

We’ve already raised over $16M, and we’re excited to collaborate with more innovative investors like you. Join us before the campaign ends on February 18th.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

Monogram’s Livestream on Wednesday, February 16th, is a MAJOR event for our company and perhaps even the industry. Monogram will demo a navigated active sagittal cutter - this is the first of its kind; no such product currently exists. Hitherto, we have been working in stealth, filing numerous patents (12 patents filed and National Science Foundation Award) and developing at an incredibly aggressive pace. Despite running a public-facing crowdfunding campaign, we have been relatively discrete regarding details of technical progress to the public. Some industry experts have thought some of our ambitions impossible.

Many have asked us the significance of a live stream. Why not record an event and share that with the world? Because the largest players in our market representing over $150B of market value and numerous orthopedic surgeons and industry insiders will be in attendance. Registration for a live broadcast forces attendance. Are we just developing a solution in search of a problem, or have we identified a meaningful market opportunity?

We believe the industry attendance numbers speak for themselves.

Join the Monogram Live Product Reveal, where the Monogram robot will perform surgery on a human knee!  Details below:

Wednesday, February 16th, 2022 @ 3 PM CST
Register: https://lnkd.in/eJCdKfQx

Will you also join us?

Greetings,

Big shoutout and thanks to our investors from the entire Monogram team!

With your support, we just reached $15M on StartEngine.

That’s one serious level up.

Now, we’re ready to keep the ball rolling, finish our campaign strong, and continue chipping away at our ambitious goals!

It’s taken some serious grit and determination, but we continue to make technical advances and progress towards our objectives every day. Our mission is to try and advance the standard of care in orthopedics with innovative technology solutions.

With your support, we know we can do it.

Become a shareholder today before this opportunity ends on February 18th.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

The Company previously filed a supplement on December 23, 2021 announcing a final closing date of January 27, 2022. Due to fundraising delays caused by COVID-19, the Company has determined it is in its best interest to extend the offering such that the last day on which subscriptions will be accepted is Friday, February 18, 2022.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

Please note that the Monogram Live Product Reveal, where the Monogram robot will perform surgery on a human knee, will be postponed until Wednesday, February 16th, at 3 PM CST. 

As a reminder, if you have not already done so, please register for the event here:

Details: Wednesday, 16 February 2022, 3:00 PM CST
Registration Link: https://event.webinarjam.com/register/10/zywr3tz

Greetings,

Monogram has just reached a jaw-dropping $14M in funding!

Our dedicated team seeks to push forward the orthopedic market, currently dominated by four market giants that dominate the joint replacement industry and block technological innovation.

With up to 10% of all knee and 15% of hip replacements failing annually, patients need better solutions now - and fast.

We’re hoping to set the next standard for the orthopedic industry with groundbreaking surgical robotics and 3D printed press-fit implants.

Our campaign ends in two weeks. Help us create a new orthopedic paradigm and invest today.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Greetings,

Guess what? Monogram just hit $13M on StartEngine, and we couldn’t have done it without our incredible investors.

There’s no time like the present to bring new innovation into the joint replacement market - an industry that affects millions of lives…but not necessarily for the better.

Until now, the $20B joint replacement industry has failed to incorporate modern technology to provide patients with a better quality of life.

Monogram is changing that, and we need your help to do it.

Our next-level precision surgical robotics and 3D-printed prosthetics are designed to improve patient outcomes and, at the end of the day, give people their freedom and independence back.

Let’s keep up the momentum. Invest today before this opportunity ends on January 27th.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Watch the Monogram robot perform surgery on a human knee!

Monday, January 24th, 2022 @ 3 PM CST
Register: https://lnkd.in/eJCdKfQx

Monogram is pleased to announce that it has received an award notice from The National Science Foundation (NSF) for its application "Development of a tracking system for computer-assisted surgery." The SBIR Phase I award will support the research of a novel Monogram tracking system designed to mitigate the occlusion limitations of conventional line-of-sight systems while reducing the OR footprint, lowering capital cost, and minimizing patient trauma associated with secondary incisions. Monogram has filed for patent protection for these novel concepts.

"It is an incredible honor to be chosen for such a prestigious award," said CEO Ben Sexson. "It's a significant endorsement that speaks to the caliber of our team and ideas as well as the tremendous efforts our company is making to further the field of orthopedic medicine. We are especially thankful to Northern Digital for their support with this application."

The NSF follows a rigorous review process, approving a small number of the full proposals. Per the NSF's Program Solicitation document, "the SBIR/STTR Phase I Programs are highly competitive. While success rates vary year-to-year, approximately 10-15% of the full proposals submitted are selected for an award. Thus, there are many qualified businesses applying to the program each year that do not receive funding." The Small Business Innovation Research Program awards such grants in phases. The Phase I award of $256,000 will help support proof of concept refinement. Monogram intends to file for a more significant Phase II award pending successful completion of Phase I activities. Funding rates for Phase II applications tend to be higher. Once a small business is awarded a Phase I SBIR/STTR grant (up to $256,000), it becomes eligible to apply for a Phase II (up to $1,000,000). Small businesses with Phase II funding are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.

"Operating rooms can get very crowded, and the footprints are often not conducive for conventional tracking methods," said CMO Dr. Doug Unis. "And while navigation offers considerable clinical benefits, secondary incisions and similar considerations are not ideal for patients. To receive recognition from such a prestigious organization for our efforts to advance the current state-of-the-art in surgical robotics is a tremendous achievement."    

The National Science Foundation (NSF) is an independent agency of the United States government that supports fundamental research and education in all the non-medical fields of science and engineering.  

We’ve had a powerful crowdfunding raise so far - and wow, does time fly by fast these days. 

The end of our campaign is just 1 month away, and we know it’ll go by in the blink of an eye. 

We’ve already raised over $12 million from almost 8,000 investors in this round alone. And with the New Year approaching, Monogram’s 2022 resolution is to reach the end of our raise with a bang.

Now, we’re calling on our crowdfunding community to help us finish strong. Don’t miss out on this opportunity to become a part-owner in the startup ushering the joint replacement market into the modern era with groundbreaking orthopedic technology. 

Make your investment today.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

If you’ve been following Monogram’s startup journey, we have the perfect opportunity for you.

Tomorrow, December 20th at 3:30 CST, you can (virtually) sit across the table from Monogram CEO Ben Sexson and Founder Doug Unis to learn more about recent company updates, growth plans, and more.

Mr. Sexton brings his background as Director of R&D and Business Development at Pro-Dex, and Dr. Unis brings his experience as an attending orthopedic surgeon for the Mount Sinai Health System. 

They’ll also talk about our exciting live-stream event coming up, where we will host a product reveal with a surgeon who has never seen or used our system for the first time in orthopedic history. 

At the end of the webinar, we’ll have a live Q&A where you can ask any specific questions about what investing in Monogram could mean for you.

Seats are limited, so be sure to reserve yours before they fill up!

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Hello, Monogram investors and followers! 

We’re happy to share that we’ve just hit $12M in funding on StartEngine. A massive shoutout to all of our incredible supporters!

It’s clear that our investors believe in us, and with your support, we can continue to push the needle forward to usher in a new paradigm of joint replacement technology. 

Monogram is breaking into an under-innovated market with cutting-edge orthopedic solutions. Our mission is to catalyze a new industry standard by improving patient outcomes and long-term wellness. 

This investment opportunity is open to all individuals looking to get in on a tech-forward startup. Become an investor today to stay one step ahead. 

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

We are pleased to announce that on  Monday, 24 January 2022, at 3:00 PM CST, we will be live-streaming a cadaveric surgery with our robotic system in a first-of-its-kind reveal!  This event is a massive moment for Monogram... 

Livestream start: Monday, 24 January 2022, 3:00 PM
Registration link: https://bit.ly/3D4HLzV

If you don't have a Linkedin account you can register here.

For likely the first time in the history of orthopaedic surgery, Monogram is live-streaming a product reveal with A SURGEON WHO HAS NEVER SEEN OR USED OUR SYSTEM.  The live audience will share his real-time discovery and watch his actual first impressions - unfiltered, unedited, live!  We are incredibly thankful to our generous shareholders, whose contributions have made this exciting event possible.  We dedicate this event to you!  We appreciate your dedication to our mission.

We hope you join us!

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Greetings,

We appreciate the opportunity to update you on our second quarter's progress and provide some general comments.  

Industry Update:

The past year has undoubtedly been a challenging one for our industry. Third-party reports trusted by management indicate that approximately 760,240 primary TKA procedures were conducted in the United States in 2020, compared to 884,000 TKA procedures in 2019. This decrease in primary TKA procedures represents a year-over-year decrease in surgical volume from 2019 to 2020 of 14% for primary TKA procedures. While we believe this decrease is transitory and related to the effects of the COVID-19 pandemic, the reduction exceeded our expectations. A silver lining is that year-over-year implant ASPs remained stable and, in some cases, increased slightly. 

The most significant macro trend that has directly impacted Monogram is manufacturing lead times. Anecdotally, we are seeing lead times getting pushed across the board. For example, manufacturers that previously quoted 6-8 week turnarounds have been pushing out to 10-12 week deliveries. One of our suppliers had to shut down a manufacturing cell for a short period. We have been actively managing these impacts, but they have impacted some of our development timelines. A positive is that we have been using time delays from hardware bottlenecks to incorporate software features previously planned for the second generation robot release.  

Strategy Execution:  

In the first six months of 2021, Monogram generated $628,000 in revenue from the sale of licensed implants. The Company has negotiated and executed its strategic objectives with the inventory purchased and will discontinue marketing these products as-is for the foreseeable future. Monogram is actively developing implants that will upgrade features of its licensed implants and incorporate elements from the licensed implants into novel implants. 

Notably, as part of this strategy, Monogram is now HIPAA compliant, has implemented a scalable ERP system, and has worked through some of the early kinks often associated with becoming a revenue-generating entity. The past quarter was a terrific "dry run" that has positioned our organization for our novel product launch.

The Company intends to submit a first-generation press-fit implant for FDA approval by Q2 2022. The timing for this FDA submission will depend on the availability of third-party manufactures to prepare our physical inventory to be evaluated by the FDA. The Company does not currently have any manufacturing capabilities itself for what is required by the FDA. As such, we could encounter longer production lead times or supplier disruptions that could materially impact our development timelines, delaying submission beyond Q2 2022. If we cannot submit our FDA submissions in a timely manner, it could adversely affect our financial position and ability to generate sales.

Figure 1: The first-generation press-fit TKA will feature aggressive asymmetric porous coating and is insertable both robotically and with manual instrumentation. We anticipate this product may be competitive with current offerings.

We look forward to exhibiting our products at AAOS in March 2022 for those interested in attending. We invite all of our shareholders to check out our booth (additional details to be announced)!

Development:  

Monogram has made significant technical progress this quarter. We are exceptionally proud of the team effort made to accomplish our goals. We capped our quarter with a successful end-to-end procedure run on a cadaveric specimen in our lab. The current Monogram surgical workflow is as follows: 

a) Pre-operative planning & case management: this workflow generates the patient case file, links it with important patient data (like the CT scan), and generates all necessary patient-specific inputs required for robotic execution. This workflow is highly automated. Our team has trained machine learning algorithms on many thousands of images to auto-identify patient anatomy. Currently, our identification algorithm is nearly perfect (near 100% accuracy), and our segmentation algorithm is getting close (approximately 99% accuracy). Trained operators and the surgeon will review all outputs, but we can minimize risk by implementing these powerful AI tools.      

b) Guidance application: this software executes surgeon inputs during the operation. We have implemented registration, soft tissue management, virtual implant placement, and various cut screens. We have devoted significant resources to our guidance application development. This application is how surgeons will interact with our technology, so it must be polished and flawless. A considerable advantage of navigated robotic execution is the ability to help surgeons properly tension ligaments before making cuts via predictive simulations.  

Figure 2: The guidance application allows the surgeon to interact with the robot during the case.  An advantage of navigated robotics is the ability to balance soft tissues before making cuts.

c) Autonomous robotic execution: with inputs from the surgeon entered through the guidance application, our software autonomously executes optimized bone cuts. We are implementing highly complex patient-specific workflows to facilitate dynamic cut paths that are specific to the patient. As far as we know, competitive systems do not do this. Cut boundaries of competitive systems appear to correspond to the chosen implants (notably to generic implants). We believe this could cause unfinished cuts (for example, the medial posterior portion of tibial resections). 

Developing cutting tools that overcome the numerous challenges of active robotic execution has not been easy. For example, vibration is a significantly increased challenge for an active robotic system. When a surgeon is holding the cutting tool, it absorbs considerable vibration, but there is no such damping with active systems.  We have prototyped two different novel cutting end-effectors intended to optimize different cut types and applications. We also expect to receive the second build of our robot carts with many design improvements in December. 

Ultimately our internal development goal is to commercialize a robotic system that is cheaper and faster than a manual procedure. Stryker has already demonstrated the cost savings vs. manual approaches with Mako (Robotic arm–assisted knee surgery: An economic analysis. (2020). The American Journal of Managed Care, 26(7). https://doi.org/10.37765/ajmc.2020.43763). Our goal is now to push the envelope on cost with cheaper hardware and to overcome, in our view, the most significant barrier to adoption, speed. We have our work cut out for us. Still, if we are to disrupt the orthopedic market by making robotics ubiquitous, it will require significant advances to the current state of the art, especially execution speed. As a benchmark, current robotic systems take on average over an hour to complete a TKA (Kayani, B., Konan, S., Huq, S. S., Tahmassebi, J., & Haddad, F. S. (2018). Robotic-arm assisted total Knee Arthroplasty has a learning curve of seven cases for integration into the surgical workflow but no learning curve effect for accuracy of implant positioning. Knee Surgery, Sports Traumatology, Arthroscopy, 27(4), 1132–1141. https://doi.org/10.1007/s00167-018-5138-5). We believe there are opportunities to streamline robotic execution.

d) Implants: as we shared previously, Monogram is commercializing via a multi-generational product release strategy. We believe it prudent to kick-off our robotic launch with an implant that is insertable both robotically and with manual instrumentation (like every other robotic system today) and similar to devices with which surgeons are familiar. Our robot is the "trojan-horse" for implant sales. Once placed, we believe our robots will facilitate upselling of differentiated novel designs.

Our first-generation Mongoram TKA will capitalize on what we view as one of the most significant growth opportunities in large joint reconstruction, the cementless knee segment.  Uncemented TKA's are projected to grow by an estimated 400,000 procedures from 2020-2024 ($1.21 billion). Notably, ASPs on cementless knees are also higher than cemented (about 10% higher). Cementless TKAs accounted for 42% of Stryker's TKA volume in 2020, up from 30% in 2018. Monogram will be starting with a press-fit TKA that we think could be competitive with the current state of the art. We believe we are early to this opportunity (for example, one of the prominent four players doesn't currently have a competitive uncemented TKA). We believe uncemented TKA's is where the market is quickly moving, and we will have a product to address this growing opportunity.   

Figure 3: Monogram has licensed the rights and supply pricing cap for the supply of an FDA-approved partial knee.  The Company plans to incorporate the partial knee for robotic execution once the TKA application enters V&V.

As mentioned above, the timeline for submitting our first-generation implant is by the second quarter of 2022. We are working extremely hard to improve that timeline. Notably, we have licensed the rights to an FDA approval partial knee. Our development plan is to submit our robot for FDA approval for the total knee application and then submit for a partial knee application as quickly as possible. We should note that our team is also developing manual instrumentation to enhance the marketability of our implant system.

In summary, we have made considerable progress, but work remains. Over the next few months, we expect to file on the order of 4 to 5 additional patents based on our recent learnings. We take heart with every technical headwind we face, knowing this is a challenging and non-trivial exercise to replicate.

Important Next Steps: Monogram intends to selectively reveal our products to significant industry stakeholders over the coming six months. To date, while Monogram has undoubtedly communicated with others in the industry, we have only ever hosted one major strategic in our facility, and that was well over two years ago (before relocating to Austin and building our team). We have our final internal cadaver lab scheduled for the fourth quarter of 2021, after which we intend to reveal our progress to select industry peers strategically in addition to the public. Given the intellectual property and novel approaches to certain technical hurdles, we are thankful to our shareholders for letting the development efforts mature privately and giving us the time and space needed to focus our engineering efforts. We are incredibly grateful for your dedication to our mission. In March 2022, Monogram intends to exhibit at the AAOS meeting.    

Fundraising:

Thank you to everyone who has joined the Monogram journey. As a management team, we very much appreciate you. We want to make sure all of you are well aware that we expect to continue accessing capital as we work to advance our technology. We think this is a necessary step in building a company with such a complex product.  We anticipate a Series-C capital raise will be forthcoming. We believe ongoing access to capital is in the best interest of our shareholders as we continue to devote significant capital resources to our development efforts.    

Thank you for your continued support and commitment. 

Kind regards,

Benjamin Sexson, CEO

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

We are very excited to announce that we’ve reached an astounding $11M in funding from our current StartEngine round. 

The brave team at Monogram is diving headfirst into the previously undisrupted $19.6B joint replacement market with cutting-edge AI that’s about to shift the industry norm completely. 

By combining highly personalized, 3D printed, and press-fit joint implants with high precision navigated surgical robotics, the market is about to witness something never seen before - a new paradigm for surgical robotics and implant design. 

Monogram’s system is set to be the first of its kind. Become an investor today to stay one step ahead. Invest now!

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Hi,

We'd like to invite you to join us on Tuesday, October 5th at 3 PM EST for a Live Investor Webinar where you will hear a series of pitches from some of the most notable and exciting private offerings currently available for investment through Regulation A.

This webinar features Monogram's CEO and Co-Founder, Ben Sexson, as well as 2 other disruptive startups from some of this year's fastest-growing markets including reAlpha and NowRx. We’ll also be joined by the Co-Founder and VP of Marketing at Rocket Dollar, to discuss how investors can better leverage self-directed IRAs to invest in opportunities Reg A+, crypto, real estate, and more. Learn how these companies are revolutionizing their respective industries and hear directly from the founders about their plans for the future.

You can register here today - spots are limited!

Kind regards,

Monogram Orthopedics

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

We are pleased to announce that our crowdfunding campaign on StartEngine recently surpassed $10M in funding.

Right now, when you invest, you can receive up to 10% bonus shares!

Investors that invest at least $5,000 in this offering will receive a 5% bonus, and investors that invest at least $10,000 will receive a 10% bonus on their investment.

Join thousands of investors worldwide by investing in Monogram's mission to disrupt this $19.6b market by combining high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes.

Keep following for more updates on how Monogram uses high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes. Support our mission to shape the future of joint replacement and click here to learn more and invest in Monogram through our page on StartEngine.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Greetings,

I appreciate your interest in Monogram. In our last webinar, we promised to mix things up and bring in an industry expert to ask us questions from an institutional perspective. We've delivered!

Matt Taylor, CFA Managing Director at UBS, has agreed to host us for a lively discussion about all things Ortho! We provide more details on Matt's credentials below, but as a headline, he leads US Medical Supplies and Devices equity research for UBS, a major investment bank and one of the largest private banks in the world. Matt and his team actively cover all the major ortho players in the space.  

Matt has been following the Monogram story. We asked him to host a call for our community and ask us anything any knowledgeable ortho investor might ask or want to know; no holds barred.

The call will be on Thursday, 30 Sep 2021, at 10:00 AM EST.  Register HERE

The discussion with Monogram's CEO Ben Sexson and CMO Doug Unis will be unscripted and include live audience Q&A.  

Discussion Topics Include:

• The current state of robotics with thoughts on solutions from the established players.

• Monogram's solution and vision for differentiation in robotics.

• Understanding Monograms cutting edge surgical tools and personalized implants.

• Views on where robotics can go in Ortho in 5-10 years.

You can register here.

About Matt Taylor, CFA:

Matt Taylor is a Managing Director and leads coverage of US Medical Supplies and Devices equity research at UBS. Matt has received recognition for his work as a MedTech analyst, achieving a top-5 position and 'runner-up' ranking in the 2019 Institutional Investor poll and he was named an 'up-and-comer' in the 2011-13 surveys. Prior to joining UBS, Matt was the senior analyst covering Medical Supplies and Devices at Barclays, joining the organization as a senior associate in 2009. Matt also worked as an associate analyst in MedTech at BMO Capital Markets from 2007-2009 and began his career in finance working in a business risk role at Morgan Stanley. Matt was trained as a biomedical engineer and holds a BS in Biomedical Engineering from Boston University, an MBA from Fordham University, participating in the Beijing MBA program, and is a CFA Charterholder.

Kind regards,

Ben

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

By attending this event, you understand and agree that your name, company name, and email address may be shared by UBS with the speaker(s) who led or participated in the sessions you attended. Please send an email to dl-access@ubs.com<mailto:dl-access@ubs.com> if you do not wish this to occur.

Notice to Public Officials/Government Employees: UBS seeks to comply with applicable laws, regulations and policies concerning the entertainment of public officials and government employees (including those of state-owned entities). Compliance with the rules applicable in your jurisdiction or to your agency is your responsibility, and we cannot advise you about such rules. If the rules or policies applicable to your agency allow you to participate in this event, and you would like to attend, please contact your UBS Salesperson for more information about our registration procedures. Please inform your UBS Salesperson if your agency's rules or policies require you to pay all or any part of the costs of attending this event, as alternative arrangements may need to be made. You will also be responsible for any reporting obligations to departments/agencies external to your agency.

When you receive UBS Access Invites (including, but not limited to, invitations to participate in UBS corporate access events, UBS analyst marketing events, UBS conferences, UBS field trips, UBS expert events, and the like) or are otherwise informed of the events et al. to which they relate, you agree not to copy, revise, amend, create a derivative work of, or in any way commercially exploit the UBS Access Invites. You further agree not to pass along, disclose or forward the UBS Access Invites, or information regarding the events et al. to which they relate, to any third party for any purpose, without the prior written consent of UBS. The foregoing restrictions on use apply to all UBS Access Invites that you may receive, irrespective of the means through which they are communicated to you.

This communication is issued by UBS AG and/or any of its subsidiaries and/or any of its affiliates ("UBS").

In the United States, this communication is issued by UBS Securities LLC (member NYSE, FINRA and SIPC) or by UBS Financial Services Inc. (member FINRA and SIPC), both of which are subsidiaries of UBS AG, or solely to US institutional investors by UBS AG or by a subsidiary or affiliate thereof that is not registered as a US broker-dealer (a "non-US affiliate"). Transactions resulting from a communication distributed by a non-US affiliate must be effected through UBS Securities LLC or UBS Financial Services Inc.

Neither UBS nor any of its directors, officers, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this communication or reliance upon any information contained herein.

Intended for recipient only and not for further distribution without the consent of UBS.

Please inform UBS if your organization’s internal policies do not permit you to accept this invitation. UBS assumes otherwise that your participation at this event is in compliance with your organization’s policies and that any necessary internal notifications have been made by you.

Please apply the requisite security measures and take all reasonable steps in accordance with good industry practice to defend yourself against fraud or cyber-attacks, including, but not limited to updating your computer systems and security software on a continuous basis (e.g. by installing recommended security patches, observing customary technical security measures, in particular the installation of up-to-date firewalls and antivirus programs).

The use of e-mail can involve substantial risks - for example, information can be intercepted, corrupted, lost, destroyed, arrive late or be incomplete. E-mails can also contain corrupted files, viruses, links or other destructive or deceptive items that could harm or interfere with your computer or device. E-mails could also be sent by people who try to trick, mislead or deceive others into sharing information, particularly personal or financial information, under false pretenses. By allowing UBS to contact you by e-mail, you understand that communications sent via e-mail are not secure or error-free, and accept the risks that come with communicating with UBS via e-mail. You also accept and agree that UBS has no liability or responsibility for any loss or damage resulting from the use of e-mails or for any losses that you might suffer as a result of communicating with UBS via e-mail.

If you do not want to receive such communications by email please click unsubscribe and we will continue to send materials by post. If you would like to cease receiving all communications or have any requests please contact dl-access@ubs.com<mailto:dl-access@ubs.com>

We are pleased to announce that our crowdfunding campaign on StartEngine recently surpassed $9M in funding.

Right now, when you invest, you can receive up to 10% bonus shares!

Investors that invest at least $5,000 in this offering will receive a 5% bonus, and investors that invest at least $10,000 will receive a 10% bonus on their investment.

Join thousands of investors worldwide by investing in Monogram's mission to disrupt this $19.6b market by combining high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes.

Keep following for more updates on how Monogram uses high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes. Support our mission to shape the future of joint replacement and click here to learn more and invest in Monogram through our page on StartEngine.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Join us on Tuesday, August 31st at 5:00 PM ET for a live investor webinar! In this webinar, Benjamin Sexson, CEO, and Doug Unis, Founder and Chief Medical Officer of Monogram will discuss the company's current crowdfunding campaign on StartEngine, the development progress of Monogram's innovation in orthopedic medicine, and host a live Q&A. You won't want to miss this, and spots are limited, so reserve your seat today.

Keep following for more updates on how Monogram uses high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes. Support our mission to shape the future of joint replacement and click here to learn more and invest in Monogram through our page on StartEngine.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

The future of orthopedic medicine is personal, and Monogram is on a mission to transform the $19.6 Billion market.

Reasons to Invest in Monogram:

• World-class team: led by a team of experts in robotics and medical technology, and advised by surgeon consultants from institutions such as Columbia and Icahn School of Medicine.

• Expecting revenues in 2021: we expect to start generating revenue from implants sales in 2021 and have signed strategic contracts with two Monogram distributors and recruited the Senior Director of US Sales from our manufacturer to support early sales efforts.

• Already raised $16.7M from 6,793 investors: we have been through 3 successful financing rounds and continue to execute.

• Established product-market fit: the leading orthopedic robot on the market (technology from a startup acquired in 2013) outsells its next largest competitor over 12-to-1 with an 87% share.  Our VP of Engineering helped develop that technology. Together with our team's support, we want to build the future of robotics.

• Novel technology for the massive growing market: The joint replacement market is approximately $19.6BN, with over 1 million knee replacements per year. We believe we will be one of the first to market with our technology and eight patent filings.

• 8 Patent Applications Filed: We believe we will be early to market with our novel technology and a Freedom to Operate on our knee implant.

Keep following for more updates on how Monogram uses high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes. Support our mission to shape the future of joint replacement and click here to learn more and invest in Monogram through our page on StartEngine.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Monogram Featured in Newsweek! 

We are excited to announce that recently Monogram Orthopedics was featured in a Newsweek article! Newsweek covered our investment opportunity and how our revolutionary surgical robotics fixes industry-wide issues. It is an honor to be named as a leader at the forefront of industry change. Check out the full article here.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

We completed our first end-to-end system cut test run through the guidance application.  You can watch a teaser here (https://youtu.be/u7NUejgMPsE)!

Monogram has implemented a pipeline that includes auto-segmentation of patient scans and surgical planning for robotic execution with our guidance application. We successfully ran our first end-to-end system test, including registration, robotic execution, and implant placement, all within the guidance application.

The next steps include many system optimizations and known enhancements, but we now largely have the architecture in place to accelerate those efforts. This cut test was the culmination of an incredible amount of work and coordination between teams.

Our next goal is to run our first-time studies within 2-3 sprints (targeting the end of August). We have highly ambitious cut time goals, and our team is pushing this extremely hard.

We look forward to hopefully sharing more in-depth information and video when the timing is right! Thank you all for your incredible support.

Keep following for more updates on how Monogram uses high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes. Support our mission to shape the future of joint replacement and click here to learn more and invest in Monogram through our page on StartEngine.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.  

We are pleased to announce that our crowdfunding campaign on StartEngine recently surpassed $8M in funding.

Right now, when you invest, you can receive up to 10% bonus shares!

Investors that invest at least $5,000 in this offering will receive a 5% bonus, and investors that invest at least $10,000 will receive a 10% bonus on their investment.

Join thousands of investors worldwide by investing in Monogram's mission to disrupt this $19.6b market by combining high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes.

Monogram is pleased to announce that on Monday, March 22nd, 2021, we completed our first Total Knee Arthroplasty ("TKA") procedure as a company and will now be generating revenue. Facilitating the requirements needed to perform our first case is a significant accomplishment for Monogram and the culmination of a tremendous team effort.  

Monogram is now:

• HIPAA compliant
• has implemented an ERP system with lot tracing
• has secured implant component supply
• has established distribution relationships
• has implemented several critical insurance policies
• has run its first cadaver lab in its Austin facility

"Our philosophy has always been to build an operating business as quickly as possible, which means much more than having competitive products," said CEO Ben Sexson. "The basic infrastructure and systems required to support and scale growth in our highly regulated market are demanding and cannot be overlooked. Pulling all the pieces together to facilitate sales in such a highly regulated market is a major first step towards our goal of building a real orthopedic company.  We believe the first dollars of revenue are always the hardest."

Monogram has not provided sales guidance but would like the investors to calibrate expectations appropriately. "Aggressively driving sales requires a significant working capital investment, and the most compelling components of our product pipeline remain in development and our focus," said CEO Ben Sexson. "We want to build a company that can scale at the appropriate time. The goal right now is forward-thinking, and we are focused on the long-term.  In the long-term, innovative products that improve patient lives are what matter to us most." 

 Monogram expects to continue generating revenues and remains optimistic about its ongoing growth prospects.

We are always looking for ways to engage with our community.  We get many clinical questions. We thought it would be a great idea to allow our shareholders or individuals interested in Monogram to engage with our founder surgeon, Dr. Unis, and ask him any clinical questions you may have…for example...

• Get his thoughts on stem cell treatments and research

• Get his thoughts on when to get knee replacements

• What to expect and how to improve your outcomes

• Get his input on surgical techniques and his preferences

• Get insights on what to ask your surgeon

This “Ask Me Anything” event will be an open opportunity for you to engage in a constructive conversation.  Our CEO, Ben Sexson, will also be available to help answer any questions about Monogram.

If you are interested in participating, please register below:

Thursday, 8 April 2021, 6:00 PM ET
Registration link: https://event.webinarjam.com/channel/monogram_ama

We just passed the $5,000,000 mark! Thank you to all of our investors so far for your support!

Don't forget that if you have already invested, you can invest multiple times during a campaign; it's not just a one-time investment!

Registration Link: http://bit.ly/3ustHwZ

Details: Wednesday, March 10th @ 10:00 AM Pacific Time (US and Canada)

Monogram is pleased to announce it has successfully executed a license agreement for an FDA-approved Unicondylar Knee Arthroplasty ("UKA") implant design from an established orthopedic manufacturer. Monogram intends to prioritize the launch of total knee and partial knee robotic applications.    

"The orthopedic market today is too siloed. Knee teams optimize knee products. Hip teams optimize hip products. Spine products are a completely different focus altogether. After the fact, large organizations try to force-fit platform technologies into these siloes," said CEO Ben Sexson. "Elon Musk explains this organization problem perfectly here. Monogram is building an orthopedic platform technology. We believe an orthopedic robot capable of addressing multiple clinical applications with a single-arm simplifies the capital equipment sales process with hospitals and will be massively differentiated. Integrating partial knees and other products into our robotic platform is critical for this."

Monogram's strategy is to develop a single, highly robust robotic platform technology that can address clinical opportunities across significant orthopedic applications, for example, knees (both total and partial), hips, shoulders, ankles, and spine. Monogram expects to begin developing its partial knee application when it enters V&V testing on its total knee application.

"If you look at Mako and their success, they started with partial knees, and after Stryker acquired them, they launched the total knee application in 2015," said Chief Medical Officer Dr. Doug Unis. "To compete with Mako, at a minimum, we will need robotic prep for both a total knee and a partial knee. Longer-term, we plan on addressing hips and other markets."

We just passed the $3,700,000 mark! Thank you to all of our investors so far for your support!

Don't forget that if you have already invested, you can invest multiple times during a campaign; it's not just a one-time investment!

Monogram will be speaking Thursday, February 11, 2021, @ 11:30 AM ET at the OTC Markets Regulation A+ Investor Conference.  The presentation is 30 minutes and will include a management Q&A.

Here is the registration link here

Monogram is pleased to announce that it has executed a Product Purchase Agreement with its first significant hospital institution.  The company expects it could begin placing implants in patients and generating revenue as early as the first quarter of 2021 (although cautions that Covid-19 and unforeseen market factors could impact timing).     

"Being accepted by the value analysis committee of a major hospital institution is a significant milestone for our company," said CEO Ben Sexson.  "We expect to begin generating revenues very soon.  We continue to execute on our strategic initiatives, and we are extremely pleased with the progress of our product pipeline and our pace of growth.  Our goal is to become a competitor in the ortho space as quickly as possible."

Monogram management looks forward to sharing our continued progress and is thankful for our shareholders without whom this progress would not have been possible.

We just passed the $3,000,000 mark!

If you are interested, reserve your shares now before this Test The Waters period closes!  Our investment minimum is only $250.79.

AND...

Right now, you can become eligible for bonus shares just for indicating interest in an investment.  For a limited time, during our “Testing The Waters” period (which we’re in now), you can become eligible to get 10% bonus shares when you invest just for indicating your interest in an investment now (not actually investing).

BUT...

This bonus will only be available during our Testing The Water period. We aren’t sure yet how long this period will last, but it will be a limited time, so we recommend joining sooner rather than later.

Please note that even if you do not make a reservation, you can still be eligible to receive Bonus Shares by investing at least $5,000 once we open for investments.  Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever. 

Big news!  We just passed the $1,500,000 mark!

If you are interested, reserve your shares now before this Test The Waters period closes!  Our investment minimum is only $250.79.

AND...

Right now, you can become eligible for bonus shares just for indicating interest in an investment.  For a limited time, during our “Testing The Waters” period (which we’re in now), you can become eligible to get 10% bonus shares when you invest just for indicating your interest in an investment now (not actually investing).

BUT...

This bonus will only be available during our Testing The Water period. We aren’t sure yet how long this period will last, but it will be a limited time, so we recommend joining sooner rather than later.

Please note that even if you do not make a reservation, you can still be eligible to receive Bonus Shares by investing at least $5,000 once we open for investments.